Overview


According to FutureWise analysis the market for active pharmaceutical ingredients CDMO in 2023 is US$ 93.28 billion, and is expected to reach US$ 159.32 billion by 2031 at a CAGR of 6.90%.

Active Pharmaceutical Ingredients CDMO is a company that deals with developing and manufacturing active pharmaceutical ingredients and outsourcing services. CDMO refers to Contract Development and Manufacturing Organisation. Pharmaceutical active ingredients are the main ingredient in the medicine that causes the desired effects of the treatment. The active ingredient in some drugs might be more than one that acts in different ways in the body. It is also called API, drug substance, and pharmaceutical substance. 

Increasing pharmaceutical demand, research and development investment, and demand for generic drugs and biological innovations drive the market. With the rise in the prevalence of the disease and its susceptibility, the demand for new drug manufacturing, along with research, development, and trials, has also increased. Furthermore, the need for further advancements in pharmaceutical products has become the most pressing priority. Considering the new lifestyle changes and the busy life are creating havoc leading to lifestyle disorders like heart disease, Type 2 diabetes, PCOS, obesity, stroke, and many such are increasing the demand of this market, creating new opportunities as well. Recent advancements and technologies are administered in the pharmaceutical product by the significant players, again raising the possibilities for market growth. 

FutureWise Market Research has published a report that provides an insightful analysis of Active Pharmaceutical Ingredients CDMO Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that Active Pharmaceutical Ingredients CDMO Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.
  •  Cambrex
  •  Recipharm
  •  Thermo Fisher Pantheon
  •  Corden Pharma
  •  Samsung Biologics
  •  Lonza
  •  Catalent
  •  Siegfried
  •  Piramal Pharma Solutions
  •  Boehringer Ingelheim

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Active Pharmaceutical Ingredients CDMO Market:

  • In May 2022, Piramal Pharma Solutions stated that the company's new active pharmaceutical ingredient (API) plant in Aurora, Ontario, went online and completed its initial production runs.

  • In June 2021, Lonza Group invested CHF 20 million (USD 21 million) to expand its API development and manufacturing facility in China.

Global demand for various pharmaceutical drugs worldwide has become the need of the hour with rising disease prevalence, driving the market growth. The COVID-19 pandemic led to an increase in the use of pharmaceutical products and awareness campaigns, and government and non – government initiatives taken in developed and underdeveloped countries have furthermore boosted the demand for this market. Globally, investment in research and development activities was the top priority, seeing from the disease prevalence, vaccination trials, drug trials, surveys, etc. Rising pharmaceutical funds from private and public organizations have rapidly aided to the market growth. A strong focus on reaching out to the maximum population and making pharmaceutical products such as drugs and vaccines accessible and affordable was the need of the hour, creating more opportunities for public-private partnerships and, in turn, growth.

Innovative advanced technologies for upgrading the healthcare system and pharmaceutical products have fuelled the industry. However, some significant constraints are anticipated to restrain overall market growth to a specific stretch over the projected period, including the high price of the pharmaceutical products, in the availability of the products due to the manufacturing shortage. Inevitable failures of the drug and vaccine trials have again hampered the market's revenue growth.

By Product

  •  Traditional Active Pharmaceutical Ingredient (Traditional API)
  •  Highly Potent Active Pharmaceutical Ingredient (HP-API)
  •  Antibody Drug Conjugate (ADC)
  •  Others

By Synthesis

  •  Synthetic
  •  Biotech

By Drug

  •  Innovative
  •  Generics

By Application

  •  Oncology
  •  Hormonal
  •  Glaucoma
  •  Cardiovascular
  •  Diabetes
  •  Others

By Workflow

  •  Clinical
  •  Commercial

By Region

  •  North America
  •  Europe
  •  Asia-Pacific
  •  Latin America
  •  Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. In the forecast period, the Asia-Pacific region is expected to grow. Moreover, compared to North America, cost benefits in the Asia Pacific as the pharmaceutical ingredients in North America are expensive. Furthermore, the growing countries of the Asia Pacific are China, India, and Japan. China is getting more attention in the market as the chemical market of China is growing at a high pace and is likely to dominate nationwide. China and India are some of the leading pharmaceutical ingredient providers globally. This factor is expected to propel the revenue growth of this market. Increasing demand for medicines due to growing infectious diseases is likely to promote market development.
  •  Tier 1 players- established companies in the market with a major market share
  •  Tier 2 players
  •  Emerging players which are growing rapidly
  •  New Entrants
  •  Growth prospects
  •  SWOT analysis
  •  Key trends
  •  Key data-points affecting market growth
  •  To provide with an exhaustive analysis on the Active Pharmaceutical Ingredients CDMO Market By Product, By Synthesis, By Drug, By Application, By Workflow and By Region.
  •  To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  •  To evaluate and forecast micro-markets and the overall market
  •  To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  •  To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  •  We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  •  The customization Mobility Care offered are free of charge with purchase of any license of the report
  •  You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Active Pharmaceutical Ingredients CDMO Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Active Pharmaceutical Ingredients CDMO Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Active Pharmaceutical Ingredients CDMO Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Active Pharmaceutical Ingredients CDMO Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Traditional Active Pharmaceutical Ingredient (Traditional API)
        2. Highly Potent Active Pharmaceutical Ingredient (HP-API)
        3. Antibody Drug Conjugate (ADC)
        4. Others

  • 8.   Global Active Pharmaceutical Ingredients CDMO Market, By Synthesis Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Synthetic
        2. Biotech

  • 9.   Global Active Pharmaceutical Ingredients CDMO Market, By Drug Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Innovative
        2. Generics

  • 10.   Global Active Pharmaceutical Ingredients CDMO Market, By Applications Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Oncology
        2. Hormonal
        3. Glaucoma
        4. Cardiovascular
        5. Diabetes
        6. Others

  • 11.   Global Active Pharmaceutical Ingredients CDMO Market, By Workflow Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Clinical
        2. Commercial

  • 12.   North America Active Pharmaceutical Ingredients CDMO Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Active Pharmaceutical Ingredients CDMO Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe Active Pharmaceutical Ingredients CDMO Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific Active Pharmaceutical Ingredients CDMO Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Cambrex
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Recipharm
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Thermo Fisher Pantheon
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Corden Pharma
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Samsung Biologics
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Lonza
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Catalent
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Siegfried
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Viva Leisure,
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        10. Boehringer Ingelheim
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 20.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11